Zobrazeno 1 - 10
of 386
pro vyhledávání: '"Hyperprogression"'
Autor:
Yiyue Huang, Yuexiang Su, Yuanyuan Chen, Jingxuan Xu, Lu Zhu, Haowen Wei, Shuiling Qin, Yuchong Peng, Lunan Qi
Publikováno v:
World Journal of Surgical Oncology, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Purpose This study aimed to develop postsurgical progression/hyperprogression recurrence (type III-IV recurrence) prediction models for hepatocellular carcinoma (HCC) patients with macroscopic vascular invasion (MaVI) and to guide treatment
Externí odkaz:
https://doaj.org/article/0f79eb16189d43099251a74a591a24d6
Publikováno v:
OncoImmunology, Vol 13, Iss 1 (2024)
This study aimed to develop a computed tomography (CT)-based radiomics model capable of precisely predicting hyperprogression and pseudoprogression (PP) in patients with non-small cell lung cancer (NSCLC) treated with immunotherapy. We retrospectivel
Externí odkaz:
https://doaj.org/article/e25ec82eadb64ae59a20c5925f850ab1
Autor:
Qinru Zeng, Shaocheng Zeng, Xiaofeng Dai, Yun Ding, Chunye Huang, Ruiwen Ruan, Jianping Xiong, Xiaomei Tang, Jun Deng
Publikováno v:
Genes and Diseases, Vol 11, Iss 6, Pp 101279- (2024)
Murine double minute 2 (MDM2) plays an essential role in the cell cycle, apoptosis, DNA repair, and oncogene activation through p53-dependent and p53-independent signaling pathways. Several preclinical studies have shown that MDM2 is involved in tumo
Externí odkaz:
https://doaj.org/article/5c3d035b07814623999d9ce31242e788
Autor:
Francesca Romana Di Pietro, Sofia Verkhovskaia, Rosa Falcone, Giulia Poti, Maria Luigia Carbone, Maria Francesca Morelli, Albina Rita Zappalà, Roberto Morese, Zorika Christiana Di Rocco, Gabriele Piesco, Paolo Chesi, Cristina Maria Failla, Paolo Marchetti, Federica De Galitiis
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundStage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the outcome of patients with metastatic melanoma a
Externí odkaz:
https://doaj.org/article/4e3a503e397a44e9aa55f222bb49925b
Autor:
R. Riera-Sala, A. Ibarra-Morales, J. Guzmán-Casta, R. Medrano-Guzmán, A. Dip-Borunda, A. Martin-Aguilar, R. Grajales-Álvarez, R. Correa-Cano, K. Elvira-Fabián, C. Sánchez-Ríos, A. Orzuna-Vázquez, J. Rovelo-Lima, L. Martínez-Barrera, J. Rodríguez-Cid, J. Alatorre-Alexander
Publikováno v:
World Cancer Research Journal, Vol 10 (2023)
BACKGROUND: The treatment of non-small cell lung cancer (NSCLC) has undergone changes that have improved the prognosis of patients. With the advent of immunotherapy, it has been possible to prolong significantly the overall and progression-free survi
Externí odkaz:
https://doaj.org/article/a7c5e98aa75a406d91e89de7ccbf0513
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Jehun Kim, Taeyun Kim, Tae Won Jang, Hee Kang, Mi Hyun Kim, Seong Hoon Yoon, Choon‐Hee Son, Hyun‐Kyung Lee, Hyun‐Kuk Kim, Shin Yup Lee, Kyeong Choel Shin, Ji‐Yeon Han, Eun‐Ju Kang
Publikováno v:
Thoracic Cancer, Vol 13, Iss 15, Pp 2170-2179 (2022)
Abstract Background Hyperprogressive disease (HPD) is a novel pattern of the treatment course after immune checkpoint inhibitor (ICI) therapy in patients with non‐small cell lung cancer (NSCLC). This study aimed to investigate the clinical characte
Externí odkaz:
https://doaj.org/article/517e3bdb2df344c2b1eb5ef134c75b9a
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Immunotherapy using immune checkpoint inhibitors (ICIs) is a breakthrough in oncology development and has been applied to multiple solid tumors. However, unlike traditional cancer treatment approaches, immune checkpoint inhibitors (ICIs) initiate ind
Externí odkaz:
https://doaj.org/article/942abe54a28a4a12b73aa7faaba6383d
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.